Skip to main content

Table 2 Current anthropometric feature, pulmonary involvement, disease status and drug treatment of patients with dermatomyositis and antisynthetase syndrome, and control group (at the time of analysis)

From: The aerobic capacity in patients with antisynthetase syndrome and dermatomyositis

 DMASSCTRP
(n = 13)(n = 9)n = 17DM vs. CTRASS vs. CTRDM vs. ASS
Current age (years)b48.1 ± 9.446.9 ± 10.247.76 ± 4.440.9930.9600.935
Time of disease (years)7.9 ± 4.56.7 ± 3.90.785
Body mass index (kg/m2)29.2 (23.9–35.2)32.2 (31.8–35.6)28.5 (25.5–30.2)> 0.9990.0560.189
Pulmonary involvement (%)1 (7.7)3 (33.3)0.167
Disease statusb   
HAQ (0.00–3.00)0.06 (0.00–0.34)0.50 (0.00–0.75)0.451
MMT-8 (0–80)80 (80–80)80 (80–80)> 0.999
Patients’ VAS (0–10)0.0 (0.0–1.0)0.0 (0.0–0.0)0.408
Physician’ VAS (0–10)0.0 (0.0–0.0)0.0 (0.0–0.0)0.544
MYOACT (0–60)0.0 (0.0–0.0)0.0 (0.0–0.0)0.746
Creatine phosphokinase (U/L)97 (70–149)141 (85–204)0.180
Treatment   
Prednisone   
Current use (%)5 (29.4)4 (44.4)> 0.999
Dose (mg/day)0.0 (0.0–7.5)0.0 (0.0–10.0)0.337
IS or immunobiological (%)   
Current use of one or more12 (92.3)9 (100.0)> 0.999
Azathioprine5 (29.4)5 (55.6)0.666
Methotrexate6 (46.2)3 (33.3)0.674
Othersa2 (15.4)5 (55.6)0.290
Rituximab01 (11.1)
  1. ASS antisynthetase syndrome, DM dermatomyositis, HAQ Health Assessment Questionnaire; IS: immunosuppressive, MMT Manual Muscle Testing, MYOACT Myositis Disease Activity Assessment, VAS Visual Analogue Scale
  2. a Others: mycophenolate mofetil and leflunomide
  3. b Results expressed as mean and standard deviation and median and interquartile range (25th–75th)